Applications of Nanoparticles for Treating Cutaneous Infection  by Westendorf, Astrid M.
Additional studies of the enigmatic Ptch1
protein are likely to unveil novel and
illuminating cancer mechanisms.
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Applications of Nanoparticles for
Treating Cutaneous Infection
Astrid M. Westendorf1
Today, nanotechnology is finding applications in medicine. The unique physical
and chemical properties of nanoparticles can overcome barriers and allow them
to gain access to biological systems. Because of the increasing prevalence
of microbial resistance to conventional therapies, the development of novel
antimicrobials is imperative. Creating nanotechnology-based drug delivery sys-
tems with antibacterial and immunomodulatory activities may lead to novel
treatments for cutaneous pathogens.
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Nanotechnology is the design and con-
trol of matter that ranges in size
from B1 to 100 nm. The application of
nanotechnology to medicine, known as
nanomedicine, involves the use of pre-
cisely engineered materials in this
size range to develop novel therapeutic
and diagnostic modalities. The unique
physical and chemical properties of
nanoparticles, in particular their small
size and their high surface-to-volume
ratio, can overcome barriers and
allow them to gain access to biological
molecules and systems. These properties
can be used to overcome some of the
limitations of conventional thera-
peutic and diagnostic agents. Therefore,
nanoparticles can be engineered to
serve as vehicles that carry various
therapeutic agents and may be useful
in medical applications, including
targeted drug delivery, vaccine deli-
very, antimicrobials, and immunomodu-
lation (Prow et al., 2011; DeLouise,
2012).
Antimicrobial nanoparticles
Several studies have shown that nano-
particles are advantageous in several
dermatological applications (Papakostas
et al., 2011; DeLouise, 2012). One
important application with respect
to the increasing frequency of micro-
biological resistance to conventional
therapies is the nanotechnology-
based drug delivery with antimicrobial
agents.
Acne is a chronic inflammatory dis-
ease of the pilosebaceous unit. It results
from an androgen-induced increase in
the production of sebum, alterations in
keratinization, inflammation, and bac-
terial colonization of hair follicles on the
face, neck, chest, and back by Propio-
nibacterium acnes. The Gram-positive
bacterium P. acnes is a ubiquitous
member of the skin microbiota and is
found in sebaceous follicles located on
the face and back of most humans.
P. acnes is generally regarded as a com-
mensal of the skin, but certain properties
suggest that it has a pathogenic role in
acne vulgaris. Treatment of acne with
antimicrobial agents has been found to
be associated with the development of
resistance to these agents by P. acnes,
leading to treatment failure. Because
acne often requires long-term treatment
with antibiotics, there are concerns
that the development of resistance
by P. acnes may be associated with
the development of resistance by other
organisms, such as Staphylococcus
aureus and S. pneumoniae. Judicious
use of antibiotics is important, espe-
cially for a common condition such as
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acne. Thus, alternative approaches for
the antimicrobial treatment of acne are
needed.
Friedman et al. (2013) report on the
antimicrobial activities of chitosan–
alginate nanoparticles. The polysacchar-
ides, alginate and chitosan, are used
extensively to develop useful nanoparti-
cles, because of their low toxicity and
their biodegradability. Alginate is an
anionic polysaccharide derived from
brown algae; chitosan is a natural poly-
saccharide biopolymer derived from
chitin, the principal structural compo-
nent of the crustacean exoskeleton. The
antimicrobial properties of chitosan
result from its polycationic character,
which favors interaction with negatively
charged microbial cell walls and cyto-
plasmic membranes, and thus results in
reduced osmotic stability and disruption
of those membranes. Friedman et al.
(2013) demonstrated by electron
microscopy that chitosan–alginate nano-
particles induce the disruption of the
P. acnes cell membrane, thereby pro-
viding an antibacterial effect during
topical application.
Other nanoparticles, such as un-
coated titanium dioxide (TiO2), possess
antibacterial properties because of
their photocatalytic action. After UV
irradiation, uncoated TiO2 acts as a
photocatalyst and promotes peroxida-
tion of the polyunsaturated phospholi-
pid component of the lipid membrane
of prokaryotes, such as bacteria (Tsuang
et al., 2008). The most commercialized
nanomaterial with antimicrobial acti-
vity so far is nanosilver, used not only
to coat wound and burn dressings
but also to disinfect water. Its anti-
microbial effect is presumably the
result of mitochondrial toxicity, which
results from interaction with thiol
groups of internal membrane proteins,
and thus causes oxidative stress (Chen
and Schluesener, 2008). However,
these antibacterial nanoparticles have
not been studied for the treatment of
acne or the treatment of cutaneous
pathogens.
Benzoyl peroxide is a widely used
topical agent for acne. It is antiseptic
and, in contrast to antibiotics, does not
promote bacterial resistance. Although
benzoyl peroxide is an effective treat-
ment, at effective doses it is frequently
associated with the expected but
unwanted adverse event, skin irritation.
Friedman et al. (2013) demonstrated
that encapsulating benzoyl peroxide in
alginate–chitosan nanoparticles would
enhance its antimicrobial activity
against P. acnes with less toxicity to
eukaryotic cells.
Immunomodulatory nanoparticles
New research has refined our under-
standing of the immunopathophysiology
of acne. Various immune phenomena,
including both innate and adaptive
immune responses, have been impli-
cated. Cell culture experiments using
skin-derived keratinocytes and sebo-
cytes showed that P. acnes can trigger
an inflammatory response, including the
production of several proinflammatory
cytokines and chemokines. Pattern
recognition receptors of the Toll-like
receptor family have been found to
be P. acnes–responsive receptors
(Lee et al., 2010). In addition, a sub-
population of T helper type 1 cells from
inflamed acne lesions recognize P.
acnes antigens (Mouser et al., 2003).
Thus, another therapeutic goal in
treating acne is a reduction in infla-
mmation. Chitosan has been shown
to possess various anti-inflammatory
properties, and Friedman et al. (2013)
have showed that in human mono-
cytes, chitosan–alginate nanoparticles
inhibit the P. acnes-induced production
of IL12p40, a cytokine previously
shown to be involved in the inflamma-
tory response in acne. In addition, P.
acnes-induced production of IL-6
was inhibited in human keratinocytes
in the presence of chitosan–alginate
nanoparticles.
Topical retinoids are a mainstay in
acne treatment. Retinoids reduce dys-
keratosis in the pilosebaceous unit, inhi-
bit the formation of microcomedones,
and exert anti-inflammatory effects.
Among the retinoids, all-trans retinoic
acid has been shown to be effective in
topical treatment of mild to moderate
acne. However, the topical use of reti-
noic acid is commonly followed by a
high incidence of adverse effects, such
as sensitivity to sunlight, eczematous
irritation, and mild to severe erythema.
Nanopreparations of acne medications,
including formulations containing reti-
noic acid, offer similar effectiveness
and fewer side effects, thus possibly
improving patient compliance and treat-
ment outcomes. Castro et al. (2011)
demonstrated in animal studies that
retinoic acid loaded into solid lipid
nanoparticles promotes a greater
reduction in retinoic acid–induced
skin irritation than conventional formu-
lations do, but without reducing the
therapeutic efficiency of retinoic acid.
To take a step forward, Ridolfi et al.
(2012) combined the anti-inflammatory
activity of retinoic acid and the
antimicrobial efficacy of chitosan to
produce solid lipid nanoparticles
containing retinoic acid and chitosan.
These nanoparticles exhibited high
encapsulation efficiency, high physical
stability during the tested period (1
year), no cytotoxicity to keratino-
cytes, and high antibacterial activity
against P. acnes and S. aureus, findings
suggesting that they may be highly
effective in the topical treatment of
cutaneous infection.
Taken together, the results of several
studies have shown that the use of
nanoparticles has advantages in treating
many dermatological conditions.
Nanoparticle applications facilitate the
body’s response to foreign pathogens by
improving innate and adaptive immune
responses, and by increasing the
Clinical Implications
 Encapsulation of antimicrobials into chitosan–alginate nanoparticles con-
tributes to increased efficiency and reduced toxicity during topical
treatment.
 Chitosan–alginate nanoparticles allow the delivery of multidrug regimens
to combat resistant microbes.
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effectiveness and reducing the adverse
effects of antimicrobials and other thera-
peutic agents. Although these applica-
tions are promising, many interesting
questions remain to be answered and
many challenges remain to be over-
come. One important issue is the com-
parability of the results of in vitro and
in vivo studies: the results of in vitro
studies do not necessarily predict the
outcome of in vivo exposure. In addi-
tion, there are growing concerns regard-
ing the potential toxicities of materials
used to fabricate some particles. Addi-
tional studies are needed to improve our
understanding of this important field
now in development.
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Mutant BRAF: A Novel Mediator of
Microenvironmental Escape in
Melanoma?
Keiran S.M. Smalley1,2
The acquisition of mutant BRAF is an important initiating event for melanoma
development, although the process by which transformed melanocytes escape
from keratinocyte control and disseminate to other organs is not well understood.
Boyd et al. (2013) provide evidence that oncogenic BRAF contributes to the
microenvironmental escape of melanocytes through the downregulation of
E-cadherin expression via the transcriptional suppressor Tbx3.
Journal of Investigative Dermatology (2013) 133, 1135–1137. doi:10.1038/jid.2012.474
The earliest stages of melanoma devel-
opment, in which transformed melano-
cytes escape the constraints of the local
microenvironment and disseminate to
lymphatic vessels and distant organs,
are still being elucidated. Under normal
physiological conditions, melanocytes
sit at the basal layer of the epidermis
where they interact closely with sur-
rounding keratinocytes at a ratio of
about 1:5. Under these circumstances,
the two cell types exhibit a close rela-
tionship, with melanin pigment (in the
form of melanosomes) being actively
transported from melanocytes into sur-
rounding keratinocytes. The transfer of
melanin to keratinocytes (aka the tann-
ing response) is critical in providing
photoprotection to skin and serves to
limit the harmful DNA-damaging activ-
ity of solar UV radiation (Tran et al.,
2008). The process of melanin synthesis
and melanosome transport is initiated
by signals that emanate from the
keratinocytes after the UV-mediated
initiation of p53-mediated gene
transcription (Tran et al., 2008). This,
in turn, leads to the release of a-
melanocyte-stimulating hormone from
the keratinocytes and the stimulation of
melanocortin receptor 1 signaling and
melanogenesis in nearby melanocytes.
In addition to these events, keratino-
cytes also control many other aspects
of melanocyte behavior, including
growth, motility, and differentiation
(Haass et al., 2005). This regulation is
achieved through a finely balanced
signaling network involving direct cell–
cell adhesion between melanocytes and
keratinocytes, as well as the release of
paracrine growth factors. One of the key
mediators of melanocyte/keratinocyte
interaction is E-cadherin, a calcium-
dependent glycoprotein that has
important roles in maintaining the cell
architecture in epithelial tissues (Haass
et al., 2005). Loss of E-cadherin expres-
sion is an important step in the majority
of epithelial cancers, and it is a pre-
requisite for dissemination of invasive
cells from the initial tumor mass (Kalluri
and Weinberg, 2009). Typically, loss of
E-cadherin expression is part of a larger
dynamic transcriptional program that is
frequently observed in cancer cells, called
the epithelial-to-mesenchymal transi-
tion (EMT). Other features of the EMT
include the adoption of a mesen-
chymal phenotype, increased extracel-
lular matrix deposition and resistance to
apoptosis (Kalluri and Weinberg, 2009).
Under normal conditions, melanocytes
express high levels of E-cadherin (despite
being derived from the neural crest) with
homotypic E-cadherin-based adhesion
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